Stockreport

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Inc.  (NGNE) 
PDF Presented favorable safety data from Phase 1/2 NGN-401 gene therapy trial for Rett syndrome at ASGCT Annual MeetingReceived Australian HREC approval for NGN-401 trialRem [Read more]